Posts Tagged ‘pharmacology’

helen maddock

June 21st, 2010

There are many perspectives on the relationship between blue skies research and its application, perhaps none more important than the potential of what’s known as ‘translational medicine’.

Dr Helen Maddock‘s work is in this important ‘translation’ — and crosses disciplinary boundaries. For example, she’s currently investigating drug-related cardiovascular complications with biomechanical, quantitative pharmacological and biomedical techniques, and collaborating with cardiologists and cardiothoracic surgeons to study how a heart attack results in injury or death of the heart muscle.

Dr Helen Maddock is Principal Lecturer in Cardiovascular Physiology and Pharmacology at Coventry University, and is Editor of the British Society for Cardiovascular Research Journal Bulletin. She’s worked for AstraZeneca and GlaxoSmithKline as well as undertaking research at UCL’s Hatter Institute and Centre for Cardiology. Her current research includes investigating the role of reactive oxygen species, mitochondrial injury and apoptosis in myocardial stress, and also the development of novel therapies for the treatment of diseases related to the cardiovascular system.

yvonne perrie

June 19th, 2010

The necessity for new vaccines is urgent and evident. Despite humanity’s success in eradicating smallpox, two other infectious diseases — malaria and TB, remains tow of the world’s primary killers. The combination of either with HIV is lethal. Infectious agents are also implicated as causes of cancer.

There is good news, though says Professor Yvonne Perrie of Aston University. Several laboratories around the world are working on new vaccines and their delivery. Indeed her own research is focused on the advancements and strategic development of drug delivery systems to facilitate effective delivery and targeting of drugs and of vaccines.

Yvonne Perrie is Professor in Pharmaceutics and Drug Delivery, as well as being Head of Pharmacy at Aston University. She is also co-author (with Thomas Rades) of FASTtrack: Pharmaceutics – Drug Delivery and Targeting.

The specific fields of her research are the formulation engineering of vaccines (including conventional and DNA vaccines); enhancing solubility and delivery of bioactive molecules using colloid science and technology; the delivery of drugs, vaccines and gene therapies using liposomes, niosomes and other novel particulate systems; the design, physicochemical characterisation and development of non-viral systems for gene delivery; tissue engineering and regenerative medicine as well as enhancing learning methods in Pharmacy Education.

roger mcfadden

June 18th, 2010

Generally speaking, the more specific a drug is for its target, the fewer unwanted side-effects there are. The huge potential of monoclonal antibody therapy, pharmacologist Roger McFadden argues, may provide the magic bullet that will enable us to tackle currently intractable diseases because of its highly targeted potency.

Roger McFadden, author of Introducing Pharmacology: For nursing and healthcare, is a Senior Lecturer in Pharmacology in the Faculty of Health at Birmingham City University.